Is 2-deoxy-2-[18F]fluoro-D-glucose PET/CT acquisition from the upper thigh to the vertex of skull useful in oncological patients?
Data
2015Autore
Salvatore, Barbara
Caprio, Maria Grazia
Fonti, Rosa
D’Amico, D.
Fraioli, F.
Salvatore, Marco
Pace, Leonardo
Metadata
Mostra tutti i dati dell'itemAbstract
Aim: To assess whether performing routinely 2-deoxy-2-
[18F]fluoro-D-glucose PET/CT (18FDG PET/CT) scan
from the upper thigh to the vertex of skull is clinically
relevant.
Materials and Methods: 3502 (1634 female; mean-age
60+16) consecutive patients undergoing 18FDG PET/CT
were retrospectively analyzed. Patients were divided in 10
groups according to primary malignancy. Chi-square
analysis was used to assess differences among
proportions. A p value < 0.05 was considered significant.
Results: 18FDG PET/CT was positive in head district in
130/3502 (3,7%) patients. In all patients lesions were
unknown before PET/CT examination. PET/CT showed
158 positive brain/head uptake in the 130 patients. The
158 lesions were localized in: brain (43/158; 27%), bone
(52/158; 33%), lymph node (1/158; 0,6%), soft tissue
(55/158; 35%) and other sites (7/158; 4,4%). According to
each group, patients were positive in the head district in
1.0% for Gastrointestinal Cancer (7/690), 3.0 % for
Genitourinary Cancer (3/101), 3.7 % for Haemathologic
Cancer (59/1590), 2.7 % for Gynaecologic Cancer
(3/112), 7.8% for Head-Neck-Thyroid and Parathyroid
Cancer (26/331), 3.5% for Breast Cancer (7/200), 2.6%
for Lung Cancer (7/271), 3.4% for Melanoma (2/59),
7.4% for Sarcoma (2/27), 11.6% for Unknown Primary
Tumour (14/121). Conclusion: Our data show a relatively high incidence of
brain/head lesion in patients with Unknown Primary
Tumour.